Therapeutics M&A Transactions

Guardant Health boosts liquid biopsy tech with MetaSight Diagnostics acquisition. Deal valued up to $150M, expanding early cancer detection and disease identification.

Shionogi & Co., Ltd. invests $2.5 billion in RADICAVA, building a rare disease platform and enhancing its ALS treatment offerings.

AI safety leader Anthropic buys Coefficient Bio for $400M in stock, boosting its life sciences capabilities and drug discovery tech.

Global pharma major Lupin Limited completes acquisition of VISUfarma B.V., significantly expanding its ophthalmology portfolio and European market reach.

Cyclerion Therapeutics

Korsana Biosciences and Cyclerion Therapeutics merge, backed by $380M financing. Focus on advancing Alzheimer's drug KRSA-028 and neurodegenerative pipeline.

Axsome Therapeutics

Axsome Therapeutics secures global rights to balipodect, a novel PDE10A inhibitor, aiming to enhance its neuroscience portfolio for neuropsychiatric conditions.

Biogen secures Apellis Pharmaceuticals in a $5.6 billion deal, enhancing its immunology and rare disease offerings with two approved therapies and expanding nephrology reach.

Eli Lilly and Company announces $6.3 billion acquisition of Centessa Pharmaceuticals, expanding its neuroscience focus on sleep-wake disorder treatments.

Biogen Inc. secures Apellis Pharmaceuticals for $5.6 billion, enhancing its rare disease and immunology portfolio with key therapies for kidney conditions and macular degeneration.

Gilead Sciences acquires Ouro Medicines for $1.675B upfront, plus milestones, to advance its autoimmune T cell therapy pipeline.

Novartis secures a next-generation PI3Kα inhibitor for $2B, enhancing its targeted breast cancer therapy pipeline and precision medicine focus.

Paratek Pharmaceuticals

Paratek Pharmaceuticals integrates Radius Health, establishing a $1 billion specialty commercial platform with NUZYRA, XHANCE, and TYMLOS, backed by B-FLEXION Life Sciences.

BriaPro Therapeutics Corp. secures exclusive rights to Soluble CD80 (sCD80) from BriaCell Therapeutics Corp. in a strategic oncology pipeline consolidation.

Zevra Therapeutics divests AZSTARYS® and KP1077 to Commave Therapeutics for $50M, resolving litigation and reinforcing its rare disease strategy.